BioCentury
ARTICLE | Clinical News

ADX71149: Phase IIa data

November 19, 2012 8:00 AM UTC

Addex reported top-line data from the double-blind, placebo-controlled Part B portion of a European Phase IIa trial in 92 patients receiving stable doses of antipsychotics showing that twice-daily 50 and 150 mg ADX71149 "met the primary objectives of safety and tolerability." Additionally, the twice-daily 50 mg dose was identified as having the "optimal" benefit-risk ratio. Part B of the trial included schizophrenic patients with residual negative symptoms, residual positive symptoms and patients with an insufficient response to clozapine. Addex also said that ADX71149 showed an effect in the subpopulation of patients with residual negative symptoms, but did not disclose details. The ongoing 12-week, open-label, dose-escalation Part A portion of the trial is evaluating twice-daily 50 mg ADX71149 titrated up to twice-daily 150 mg ADX71149 in 15 patients not receiving antipsychotic medication. The trial was conducted by Johnson & Johnson's Janssen Pharmaceuticals Inc. unit. ...